Alcon Inc. - Registered Shares

Alcon, Inc. engages in the development, manufacture, and marketing of market surgical equipment and devices, pharmaceutical eye drops, and consumer vision care products to treat eye diseases and disorders. It operates through the following segments: Surgical and Vision Care. The Surgical segment offers implantable products, consumables and equipment for use in surgical procedures to address cataracts, vitreoretinal conditions, refractive errors, and glaucoma. The Vision Care segment comprises daily disposable, reusable and color-enhancing contact lenses, as well as portfolio of ocular health products, including over-the-counter products for dry eye, contact lens care, and ocular allergies, as well as ocular vitamins and redness relievers. The company was founded by Mr. Robert Alexander and Mr. William Conner on 1945 and is headquartered in Geneva, Switzerland.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

GENEVA--(BUSINESS WIRE)--Alcon to Showcase Vision Care Innovation, Including Clinical Data for its Forthcoming Reusable Monthly Lens TOTAL30, at BCLA 2021

Alcon to Showcase Vision Care Innovation, Including Clinical Data for its Forthcoming Reusable Monthly Lens TOTAL30, at BCLA 2021

Alcon Inc. (ALC) CEO David Endicott on Q1 2021 Results - Earnings Call Transcript

GENEVA--(BUSINESS WIRE)--Alcon Reports First Quarter 2021 Results

Alcon Reports First Quarter 2021 Results

GENEVA--(BUSINESS WIRE)--Alcon to Acquire U.S. Commercialization Rights to Ophthalmic Eye Drop Simbrinza

Alcon to Acquire U.S. Commercialization Rights to Ophthalmic Eye Drop Simbrinza

GENEVA--(BUSINESS WIRE)--Alcon shareholders approve all binding resolutions at the 2021 Annual General Meeting

Alcon Shareholders Approve All Binding Resolutions at the 2021 Annual General Meeting

GENEVA--(BUSINESS WIRE)--Alcon Launches Systane Hydration Multi-Dose Preservative-Free Lubricant Eye Drops in the U.S.

Alcon Launches Systane Hydration Multi-Dose Preservative-Free Lubricant Eye Drops in the U.S.

Alcon holds an upbeat capital markets day event, outlining its updated medium-term targets into 2025. A rich product pipeline and upcoming expansion plans underpin the growth and margin outlook.

Alcon: Updated Medium-Term Plan Highlights The Growth And Margin Opportunity

ALX Onconology Holdings Inc

CuriosityStream

Semtech

Upstart Holdings

TipRanks analyst ranking service pinpoints Wall Street's best-performing stocks, like Alcon, Semtech, Upstart, and others.

Top Wall Street analysts bet on these stocks for long-term growth

Alcon (NYSE:ALC) has observed the following analyst ratings within the last quarter:   Last 30 Days 1 Month Ago 2 Months Ago 3 Months Ago Bullish 1 1 0 0 Somewhat Bullish 0 2 0 0 Indifferent 0 0 0 0 Somewhat Bearish 0 0 0 0 Bearish 0 0 0 0 5 analysts offering 12-month price targets in the last 3 months for Alcon evaluate the company at an average price target of $80.6 with a high of $86.00 and a low of $75.00.

Where Alcon Stands With Analysts

GENEVA--(BUSINESS WIRE)--Alcon Publishes Agenda for Annual General Meeting

Alcon Publishes Agenda for Annual General Meeting

GENEVA--(BUSINESS WIRE)--Alcon to Host Virtual Capital Markets Day on March 24

Alcon to Host Virtual Capital Markets Day on March 24

FORT WORTH, Texas--(BUSINESS WIRE)--Alcon's Sue-Jean Lin Wins 2021 Dallas CIO of the Year

Alcon's Sue-Jean Lin Wins 2021 Dallas CIO of the Year

Alcon, Inc. (ALC) CEO David Endicott on Q4 2020 Results - Earnings Call Transcript

Shares of Alcon (NYSE:ALC) were flat in after-market trading after the company reported Q4 results. Quarterly Results Earnings per share decreased 8.89% over the past year to $0.41, which were in line with the estimate of $0.41.

Recap: Alcon Q4 Earnings

GENEVA--(BUSINESS WIRE)--Alcon Reports Fourth Quarter and Full Year 2020 Results

Alcon Reports Fourth Quarter and Full Year 2020 Results

Alcon, Inc. (ALC) Presents at JPMorgan Healthcare Conference - (Transcript)

Eye-care devices market is an attractive end-market supported by secular growth trends such as aging population, increased myopia prevalence, and innovation in products leading to better outcomes for patients. I believe Alcon will be able to grow above the market in the medium term, driven by near-term product flow and pipeline, increased focus, and entrenched leadership.

Alcon: Global Leader In An Attractive End-Market

Alcon, Inc. (ALC) CEO David Endicott on Q3 2020 Results - Earnings Call Transcript

Shares of Alcon (NYSE:ALC) rose 2.73% in after-market trading after the company reported Q3 results. Quarterly Results Earnings per share decreased 15.22% year over year to $0.39, which beat the estimate of $0.22.

Alcon: Q3 Earnings Insights

Alcon Inc. (ALC) CEO David Endicott on Q2 2020 Results - Earnings Call Transcript

Alcon Inc. (ALC) CEO David Endicott on Q1 2020 Results - Earnings Call Transcript

Alcon, Inc. (ALC) CEO David Endicott on Q4 2019 Results - Earnings Call Transcript

GlaxoSmithKline

The switch will increase the availability of pain and allergy drugs from GlaxoSmithKline and Alcon.

News for Alcon Inc. - Registered Shares Stock (ALC)